CN113490505A - 用于治疗tau蛋白病的tau肽抗原及与其结合的抗体 - Google Patents

用于治疗tau蛋白病的tau肽抗原及与其结合的抗体 Download PDF

Info

Publication number
CN113490505A
CN113490505A CN201980089304.0A CN201980089304A CN113490505A CN 113490505 A CN113490505 A CN 113490505A CN 201980089304 A CN201980089304 A CN 201980089304A CN 113490505 A CN113490505 A CN 113490505A
Authority
CN
China
Prior art keywords
antibody
antibodies
tau
subject
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980089304.0A
Other languages
English (en)
Chinese (zh)
Inventor
马克·I·戴蒙德
肯尼斯·德罗姆博斯基
陈代璐
维克托·马农
刘晓华
哈米德·米尔扎耶
海梅·瓦凯-阿利恰
希尔达·米尔巴哈
卢卡什·约阿希米亚克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN113490505A publication Critical patent/CN113490505A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
CN201980089304.0A 2018-11-19 2019-11-18 用于治疗tau蛋白病的tau肽抗原及与其结合的抗体 Pending CN113490505A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769281P 2018-11-19 2018-11-19
US62/769,281 2018-11-19
PCT/US2019/061928 WO2020106598A1 (en) 2018-11-19 2019-11-18 Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies

Publications (1)

Publication Number Publication Date
CN113490505A true CN113490505A (zh) 2021-10-08

Family

ID=70773408

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980089304.0A Pending CN113490505A (zh) 2018-11-19 2019-11-18 用于治疗tau蛋白病的tau肽抗原及与其结合的抗体

Country Status (5)

Country Link
US (1) US20220273779A1 (https=)
EP (1) EP3883602A4 (https=)
JP (1) JP2022513075A (https=)
CN (1) CN113490505A (https=)
WO (1) WO2020106598A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111405908A (zh) * 2017-10-27 2020-07-10 联脑科学公司 Tau肽免疫原构建体
CN113861441A (zh) * 2021-10-28 2021-12-31 南开大学 一种tau蛋白特异的纳米分子伴侣的制备方法及其在抑制tau聚集中的应用
CN114113278A (zh) * 2021-11-24 2022-03-01 中国计量科学研究院 一种基于质谱的体外诊断试剂抗体的表位定位方法
WO2023143043A1 (zh) * 2022-01-29 2023-08-03 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株
CN116549632A (zh) * 2023-03-28 2023-08-08 中国人民解放军军事科学院军事医学研究院 抗Lingo-1抗体Opicinumab的新用途及针对新用途的药物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
JP2023175325A (ja) * 2022-05-30 2023-12-12 学校法人順天堂 タウオパチーの鑑別診断法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596221A (zh) * 2009-06-10 2012-07-18 纽约大学 病理tau蛋白的免疫靶向
CN104185640A (zh) * 2011-09-19 2014-12-03 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0618968T3 (da) * 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596221A (zh) * 2009-06-10 2012-07-18 纽约大学 病理tau蛋白的免疫靶向
CN104185640A (zh) * 2011-09-19 2014-12-03 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111405908A (zh) * 2017-10-27 2020-07-10 联脑科学公司 Tau肽免疫原构建体
CN111405908B (zh) * 2017-10-27 2024-10-25 联脑科学公司 Tau肽免疫原构建体
CN113861441A (zh) * 2021-10-28 2021-12-31 南开大学 一种tau蛋白特异的纳米分子伴侣的制备方法及其在抑制tau聚集中的应用
CN114113278A (zh) * 2021-11-24 2022-03-01 中国计量科学研究院 一种基于质谱的体外诊断试剂抗体的表位定位方法
WO2023143043A1 (zh) * 2022-01-29 2023-08-03 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株
CN116549632A (zh) * 2023-03-28 2023-08-08 中国人民解放军军事科学院军事医学研究院 抗Lingo-1抗体Opicinumab的新用途及针对新用途的药物

Also Published As

Publication number Publication date
JP2022513075A (ja) 2022-02-07
EP3883602A1 (en) 2021-09-29
WO2020106598A1 (en) 2020-05-28
EP3883602A4 (en) 2023-04-12
US20220273779A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CN113490505A (zh) 用于治疗tau蛋白病的tau肽抗原及与其结合的抗体
US11739140B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
US20220204601A1 (en) Anti-tau antibody and use of same
AU2017295608B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP6641305B2 (ja) 微小管結合タンパク質タウに特異的に結合する抗体及び抗原結合断片
JP6316195B2 (ja) モノクローナル抗体および使用の方法
CN105121473A (zh) α-突触核蛋白抗体及其用途
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JP7618240B2 (ja) 脳神経系疾患の予防または治療用組成物
JP2020511963A (ja) ヒトアルファ−シヌクレインに対する抗体
JP2023554382A (ja) タウ結合化合物
WO2023206609A1 (zh) 针对p-tau 217的抗体及其用途
US20240254209A1 (en) Generation of human peanut allergen-specific ige monoclonal antibodies for diagnostic and therapeutic use
JP2022528953A (ja) 抗タウｃ３抗体及びその使用
KR102032314B1 (ko) 변이된 타우 단백질 단편 및 이의 용도
JP5924752B2 (ja) 抗汗抗原モノクローナル抗体
EP4259180A1 (en) Human ige monoclonal antibodies to antibodies to alpha-gal (galactose-a-1,3-galactose) and uses therefor
JP2021052757A (ja) 微小管結合タンパク質タウに特異的に結合する抗体及び抗原結合断片
EP4516923A1 (en) Digested ddit4l product as diagnostic marker for alzheimer's disease
CN102047112A (zh) 用于检测老化、及伴随有血管障碍的疾病的组合物、试剂盒及方法
US11397188B2 (en) Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease
WO2026039731A1 (en) Antibody genetics of radiologically isolated syndrome
HK40124151A (en) Digested ddit4l product as diagnostic marker for alzheimer's disease
WO2022099298A1 (en) Antibodies for use in the detection and treatment of heart disease
CN115135345A (zh) 中和寨卡病毒的人抗体及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211008